Short Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Rises By 241.4%

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 305,900 shares, anincreaseof241.4% from the June 30th total of 89,600 shares. Based on an average daily trading volume, of 159,200 shares, the short-interest ratio is presently 1.9 days. Currently,6.7% of the company’s shares are sold short. Currently,6.7% of the company’s shares are sold short. Based on an average daily trading volume, of 159,200 shares, the short-interest ratio is presently 1.9 days.

Sunshine Biopharma Stock Performance

Shares of NASDAQ SBFM opened at $1.43 on Wednesday. The company has a market capitalization of $6.52 million, a P/E ratio of -0.01 and a beta of 1.45. Sunshine Biopharma has a 52-week low of $1.17 and a 52-week high of $5.40. The company’s 50 day moving average price is $1.51 and its 200-day moving average price is $1.81.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The firm had revenue of $8.90 million during the quarter. Sunshine Biopharma had a negative return on equity of 21.25% and a negative net margin of 13.88%.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Sunshine Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sunshine Biopharma stock. Connective Capital Management LLC bought a new stake in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned 0.93% of Sunshine Biopharma as of its most recent SEC filing. 41.98% of the stock is currently owned by hedge funds and other institutional investors.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.